Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer.
Palafox M, Monserrat L, Bellet M, Villacampa G, Gonzalez-Perez A, Oliveira M, Brasó-Maristany F, Ibrahimi N, Kannan S, Mina L, Herrera-Abreu MT, Òdena A, Sánchez-Guixé M, Capelán M, Azaro A, Bruna A, Rodríguez O, Guzmán M, Grueso J, Viaplana C, Hernández J, Su F, Lin K, Clarke RB, Caldas C, Arribas J, Michiels S, García-Sanz A, Turner NC, Prat A, Nuciforo P, Dienstmann R, Verma CS, Lopez-Bigas N, Scaltriti M, Arnedos M, Saura C, Serra V. Palafox M, et al. Among authors: dienstmann r. Nat Commun. 2022 Nov 14;13(1):6928. doi: 10.1038/s41467-022-34580-3. Nat Commun. 2022. PMID: 36376284 Free PMC article. No abstract available.
Combined modality therapy of stage IIIC breast cancer.
Dienstmann R, Branco LG, Rezende LM, Freitas LC, Lima CF, Rodrigues GJ, Noronha Filho H, Sarmento RB, Small I, Bines J. Dienstmann R, et al. Breast J. 2011 May-Jun;17(3):331-3. doi: 10.1111/j.1524-4741.2011.01086.x. Epub 2011 Apr 8. Breast J. 2011. PMID: 21477173 Clinical Trial. No abstract available.
Barriers in precision medicine implementation among Advanced Nonsquamous Cell Lung Cancer-patients: A Real-World Evidence Scenario.
Duarte FA, Ferreira CG, Dienstmann R, Ferrari BL, Costa E Silva M, Nazareth A Junior P, Guilherme de O Salles P, Henrique C Diniz P. Duarte FA, et al. Among authors: dienstmann r. J Mark Access Health Policy. 2022 May 24;10(1):2077905. doi: 10.1080/20016689.2022.2077905. eCollection 2022. J Mark Access Health Policy. 2022. PMID: 36353186 Free PMC article.
Impact of the COVID-19 Pandemic on Cancer Staging: An Analysis of Patients With Breast Cancer From a Community Practice in Brazil.
Resende CAA, Fernandes Cruz HM, Costa E Silva M, Paes RD, Dienstmann R, Barrios CHE, Goncalves AC, Cascelli FGA, Souto AKBA, Oliveira LC, Reinert T, Andrade DAP, Passos MP, Millen EC, Zerwes F, Moraes PL, Ferrari BL, Mano MS. Resende CAA, et al. Among authors: dienstmann r. JCO Glob Oncol. 2022 Nov;8:e2200289. doi: 10.1200/GO.22.00289. JCO Glob Oncol. 2022. PMID: 36351212 Free PMC article.
XAF1 mRNA expression improves progression-free and overall survival for patients with advanced bladder cancer treated with neoadjuvant chemotherapy.
Pinho MB, Costas F, Sellos J, Dienstmann R, Andrade PB, Herchenhorn D, Peixoto FA, Santos VO, Small IA, Guimarães DP, Ferreira CG. Pinho MB, et al. Among authors: dienstmann r. Urol Oncol. 2009 Jul-Aug;27(4):382-90. doi: 10.1016/j.urolonc.2008.03.016. Epub 2008 Jun 16. Urol Oncol. 2009. PMID: 18555708 Clinical Trial.
Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs.
Markman B, Dienstmann R, Tabernero J. Markman B, et al. Among authors: dienstmann r. Oncotarget. 2010 Nov;1(7):530-543. doi: 10.18632/oncotarget.188. Oncotarget. 2010. PMID: 21317449 Free PMC article. Review.
165 results